AgomAb Therapeutics NV (AGMB)
| Market Cap | 511.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -73.44M |
| Shares Out | 48.74M |
| EPS (ttm) | -135.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,184 |
| Open | 11.35 |
| Previous Close | 11.32 |
| Day's Range | 10.44 - 11.62 |
| 52-Week Range | 9.00 - 17.45 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 32.00 (+204.76%) |
| Earnings Date | Apr 23, 2026 |
About AGMB
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFβR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFβR1 for the treatment of idi... [Read more]
Analyst Forecast
According to 3 analysts, the average rating for AGMB stock is "Buy." The 12-month stock price target is $32.0, which is an increase of 204.76% from the latest price.
News
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- P...
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“'Agomab'”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and...
Agomab Announces Closing of Initial Public Offering
ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapi...
Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
Shares of Agomab Therapeutics fell about 8% in their Nasdaq debut on Friday, valuing the Belgium-based company at $716.4 million.
Agomab Announces Pricing of Initial Public Offering
ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapi...
Agomab Therapeutics files for US IPO
Biopharmaceutical company Agomab Therapeutics filed for an initial public offering in the United States on Friday.
AgomAb Therapeutics IPO Registration Document (F-1)
AgomAb Therapeutics has filed to go public with an IPO on the NASDAQ